F. Homar

Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients.

A. Moya, F. González-Candelas, A. Payeras, 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.

A. Moya, F. González-Candelas, A. Payeras, 2014, International microbiology : the official journal of the Spanish Society for Microbiology.

Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients.

A. Moya, A. Payeras, J. Castro, 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

J. Miro, A. Curran, A. Montoliu, 2019, HIV medicine.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

I. Oyagüez, M. Casado, A. Payeras, 2012, Health Economics Review.

Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCAs) were stopped, versus continuation with FDCAs

I. Oyagüez, M. Casado, F. Homar, 2012 .